MX2018006800A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2018006800A
MX2018006800A MX2018006800A MX2018006800A MX2018006800A MX 2018006800 A MX2018006800 A MX 2018006800A MX 2018006800 A MX2018006800 A MX 2018006800A MX 2018006800 A MX2018006800 A MX 2018006800A MX 2018006800 A MX2018006800 A MX 2018006800A
Authority
MX
Mexico
Prior art keywords
formoterol
pharmaceutical composition
solvates
prodrugs
pharmaceutically acceptable
Prior art date
Application number
MX2018006800A
Other languages
English (en)
Inventor
Corr Stuart
James Noakes Timothy
Original Assignee
Mexichem Fluor Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57750288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018006800(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1521456.2A external-priority patent/GB201521456D0/en
Priority claimed from GB1615916.2A external-priority patent/GB2554092A/en
Application filed by Mexichem Fluor Sa De Cv filed Critical Mexichem Fluor Sa De Cv
Publication of MX2018006800A publication Critical patent/MX2018006800A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una composición farmacéutica. La composición comprende: (i) al menos un compuesto de formoterol seleccionado de formoterol, sales de formoterol farmacéuticamente aceptables, profármacos de formoterol, solvatos de formoterol, solvatos de sales de formoterol farmacéuticamente aceptables y solvatos de profármacos de formoterol; (ii) al menos un corticosteroide; (iii) un componente tensioactivo que comprende al menos un compuesto tensioactivo; y (iv) un componente propelente que comprende 1,1-difluoroetano (R-152a).
MX2018006800A 2015-12-04 2016-12-02 Composicion farmaceutica. MX2018006800A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1521456.2A GB201521456D0 (en) 2015-12-04 2015-12-04 Pharmaceutical composition
GB1615916.2A GB2554092A (en) 2016-09-19 2016-09-19 Pharmaceutical composition
PCT/GB2016/053812 WO2017093758A1 (en) 2015-12-04 2016-12-02 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2018006800A true MX2018006800A (es) 2018-11-09

Family

ID=57750288

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006800A MX2018006800A (es) 2015-12-04 2016-12-02 Composicion farmaceutica.

Country Status (10)

Country Link
US (3) US11559505B2 (es)
EP (4) EP3701940A1 (es)
JP (3) JP6899824B2 (es)
CN (2) CN112472689B (es)
AU (3) AU2016364650B2 (es)
BR (2) BR122020022602B1 (es)
CA (1) CA3007050C (es)
ES (3) ES2796177T3 (es)
MX (1) MX2018006800A (es)
WO (1) WO2017093758A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2017093758A1 (en) 2015-12-04 2017-06-08 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CN113288869A (zh) 2016-09-19 2021-08-24 墨西哥氟石股份公司 药物组合物
ES2877575T3 (es) 2016-09-19 2021-11-17 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende salmeterol
EP3610871B1 (en) 2016-09-19 2023-11-08 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising glycopyrrolate
GEP20217240B (en) * 2016-09-19 2021-03-25 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN109771398B (zh) * 2019-02-25 2019-09-20 广州南鑫药业有限公司 一种帕拉米韦溶液型吸入剂及其制备方法
CN110840864B (zh) * 2019-12-20 2022-02-22 广州健康元呼吸药物工程技术有限公司 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品
GB2593283B (en) * 2020-01-28 2023-09-13 Chiesi Farm Spa Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
GB202001537D0 (en) * 2020-02-05 2020-03-18 Consort Medical Plc Pressurised dispensing container
GB2593970A (en) * 2020-02-20 2021-10-13 Chiesi Farm Spa Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
FR3137830A1 (fr) * 2022-07-13 2024-01-19 Aptar France Sas Composition pharmaceutique comprenant du salbutamol

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
ATE213946T1 (de) * 1991-12-18 2002-03-15 Formoterol und budesonide enthaltende zusammensetzung
MX9704550A (es) 1994-12-22 1997-10-31 Astra Ab Formulaciones de medicamentos en aerosol.
SK284448B6 (sk) 1995-04-14 2005-04-01 Glaxo Wellcome Inc. Merací dávkovací inhalátor
DK1014943T3 (da) 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
DE69814428T2 (de) 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
EP1102579B1 (de) 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB2392164B (en) 1999-09-11 2004-04-07 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
SK286694B6 (sk) 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosólový farmaceutický prostriedok
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
AR036358A1 (es) 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
WO2004015822A1 (ja) 2002-08-08 2004-02-19 Fujikura Ltd. 電気コネクタおよびケ−ブル
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
US20060018840A1 (en) 2004-06-28 2006-01-26 Nektar Therapeutics Aerosolizable formulation comprising nicotine
ES2259915B1 (es) * 2005-03-15 2007-12-16 Laboratorio Aldo-Union, S.A. Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion.
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP2444080A3 (en) 2007-02-09 2012-05-02 Schering Corporation Stable Pharmaceutical Drug Aerosols
US8597616B2 (en) * 2007-10-22 2013-12-03 Board Of Regents Of The University Of Texas System Dry powder drug delivery formulations, methods of use, and devices therefore
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
GB0915106D0 (en) 2009-08-28 2009-10-07 Glaxo Group Ltd Process
CN103919785B (zh) 2009-10-02 2016-08-24 奇斯药制品公司 福莫特罗和二丙酸倍氯米松的药用气雾制剂
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
US20130274232A1 (en) * 2010-07-16 2013-10-17 Cipla Limited Pharmaceutical Compositions
EP2749284A3 (en) * 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and carmoterol
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
CN102362860A (zh) 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
MX2015003731A (es) 2012-10-23 2015-06-15 Cipla Ltd Composicion farmaceutica.
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
SG11201605311UA (en) 2013-12-30 2016-07-28 Chiesi Farma Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
WO2017093758A1 (en) 2015-12-04 2017-06-08 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
ES2877575T3 (es) 2016-09-19 2021-11-17 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende salmeterol

Also Published As

Publication number Publication date
EP3556347B1 (en) 2021-03-24
EP3701940A1 (en) 2020-09-02
BR112018011266A2 (pt) 2018-11-21
EP3383366B1 (en) 2020-03-25
CN112472689B (zh) 2023-01-17
AU2019202875B2 (en) 2020-03-12
CN112472689A (zh) 2021-03-12
AU2019202874B2 (en) 2020-03-12
WO2017093758A1 (en) 2017-06-08
BR122020022602B1 (pt) 2024-03-05
ES2866175T3 (es) 2021-10-19
CN108289843A (zh) 2018-07-17
BR112018011266B1 (pt) 2023-11-21
ES2869176T3 (es) 2021-10-25
US20190247339A1 (en) 2019-08-15
JP6899824B2 (ja) 2021-07-07
EP3383366B2 (en) 2024-06-05
AU2019202875A1 (en) 2019-05-16
ES2796177T3 (es) 2020-11-26
CA3007050A1 (en) 2017-06-08
EP3556348B1 (en) 2021-02-03
US20200009089A1 (en) 2020-01-09
US11559505B2 (en) 2023-01-24
EP3556348A1 (en) 2019-10-23
EP3383366A1 (en) 2018-10-10
AU2019202874C1 (en) 2020-08-06
AU2016364650B2 (en) 2019-04-04
US11559506B2 (en) 2023-01-24
JP2020073516A (ja) 2020-05-14
CA3007050C (en) 2020-12-08
EP3556347A1 (en) 2019-10-23
US11559507B2 (en) 2023-01-24
US20200069619A1 (en) 2020-03-05
JP6931383B2 (ja) 2021-09-01
JP2020073515A (ja) 2020-05-14
JP6899889B2 (ja) 2021-07-07
AU2019202874A1 (en) 2019-05-16
CN108289843B (zh) 2021-08-17
JP2019500340A (ja) 2019-01-10
AU2016364650A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
MX2018006800A (es) Composicion farmaceutica.
PH12019500579A1 (en) Pharmaceutical composition
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
PH12016502255A1 (en) Combination
MX2019003099A (es) Composicion farmaceutica.
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2018006799A (es) Composicion farmaceutica.
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
PH12019501639A1 (en) Jaki selective inhibitors
PH12019500577A1 (en) Pharmaceutical composition
MX2019003097A (es) Composicion farmaceutica.
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
MX2021010022A (es) Composicion farmaceutica.
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
NZ733451A (en) Combination therapy for pulmonary hypertension
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv
MX2021005038A (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas.
EP3459933A3 (en) Solid forms of a pharmaceutically active compound
PH12018500132A1 (en) Solid pharmaceutical compositions for treating hcv
EP3898596A4 (en) PHARMACEUTICAL COMPOUND, METHOD FOR MAKING IT AND ITS USE AS A THERAPEUTIC AGENT
WO2018096525A3 (en) Heteroaryl compounds and uses thereof
MX2019000977A (es) Composiciones farmacéuticas a base de curcumina y procedimientos para su fabricación.
MX2018010652A (es) Composiciones farmaceuticas.
TN2016000561A1 (en) Stabilized desmopressin
MX2018007326A (es) Composicion para reducir la frecuencia de miccion, metodo para elaborar y utilizar la misma.

Legal Events

Date Code Title Description
FG Grant or registration